Biomarkers, Pathways, and Targeted Therapies®
Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care
Most Popular Right Now
Precision Medicine in Oncology®
Precision Medicine—An Inevitable (Though Challenging) Goal!Andre Goy, MD, writes about implementing precision medicine, which requires a global effort from clinicians, insurance providers, government regulators, and the pharmaceutical industry.
Read more >>>